Skip to main
COLL

Collegium Pharmaceutical (COLL) Stock Forecast & Price Target

Collegium Pharmaceutical (COLL) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Collegium Pharmaceutical is a diversified biopharmaceutical company with a positive outlook due to their strong expected earnings, potential for growth in the ADHD market, successful acquisitions for expansion, and the upcoming launch of AZSTARYS. With a focus on ADHD and a well-positioned pain franchise, the company is expected to experience strong growth. This positive outlook is reflected in their Buy rating and a price target of $45 based on predicted EBITDA in 2027.

Bears say

Collegium Pharmaceutical is a company with a strong track record of strategic M&A in the ADHD and pain markets. However, recent sales performance for key products like AZSTARYS and JORNAY PM have underperformed, posing a risk to earnings and the company's ability to execute its acquisition-based growth strategy. And while the company's financials and potential for expansion into CNS and rare diseases look promising, the lack of internal innovation and the potential for further revenue erosion from the Nucynta franchise are key concerns. As such, a cautious outlook on the stock is warranted.

Collegium Pharmaceutical (COLL) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Collegium Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Collegium Pharmaceutical (COLL) Forecast

Analysts have given Collegium Pharmaceutical (COLL) a Buy based on their latest research and market trends.

According to 6 analysts, Collegium Pharmaceutical (COLL) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Collegium Pharmaceutical (COLL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.